Pteridines € EUR - Euro £ GBP - Pound $ USD - Dollar EN English Deutsch 0 × Your purchase has been completed. Your documents are now available to view. × Changing the currency will empty your shopping cart. Confirm Cancel Pteridines Official Journal of the International Society of Pteridinology ISSN: 2195-4720 First published: April 20, 1989 Editor-in-chief: Dietmar Fuchs Impact Factor: 0.366 Overview Latest issue Issues Ranking Submit Editorial About this journal Objective Pteridines is an open acess international quarterly journal dealing with all aspects of pteridine research. Pteridines are heterocyclic fused ring compounds involved in a wide range of biological functions from the color on butterfly wings to cofactors in enzyme catalysis to essential vitamins. Of the pteridines, 5,6,7,8-tetrahydrobiopterin is the necessary cofactor of several aromatic amino acid monoxygenases, the nitric oxide synthases and glyceryl ether monoxygenase (GEMO). Neopterin plays an essential role in the immune system and is an important biomarker in laboratory medicine for diseases such as HIV, cardiovascular disease, malignant tumors, among others. Topics Neopterin, dihydroneopterin, monapterin Biopterin, tetrahydrobiopterin Folates, antifolates, riboflavin Phenylalanine, tyrosine, phenylketonuria, serotonin, adrenalin, noradrenalin, L-DOPA, dopamine, related biogenic amines Phenylalanine hydroxylase, tyrosine hydroxylase, tryptophan hydroxylase, nitric oxide synthases (iNOS), alkylglycerol monooxygenase (AGMO), dihydropterin reductase, sepiapterin reductase Homocysteine, mediators of inflammation, redox systems, iron Article formats Original articles, reviews, mini reviews, commentaries, opinions on controversial subjects > Information on submission process Your Benefits Your benefits: Unique interdisciplinary forum devoted to conjugated and unconjugated pteridines Basic and clinical approach to the topic combining the fields of chemistry, biochemistry, clinical chemistry, and laboratory medicine International, authoritative editors and reviewers boosting the prestige of published papers Free language-correction services for authors from non-English speaking regions Worldwide dissemination and unrestricted access to all published articles Promotion of each published article Secure archiving by De Gruyter and the independent archiving service Portico No submission charges Pteridines is the official journal of the International Society of Pteridinology (ISP). History Pteridines was founded in 1989 and has been continued at De Gruyter since 2013. Abstracting and Indexing Pteridines is covered by the following services: Baidu Scholar Biobase Cabells Journalytics Case Chemical Abstracts Service (CAS) - CAplus Chemical Abstracts Service (CAS) - SciFinder Chronos Hub CNKI Scholar (China National Knowledge Infrastructure) CNPIEC - cnpLINKer Dimensions DOAJ (Directory of Open Access Journals) EBSCO (relevant databases) EBSCO Discovery Service EMBASE Genamics JournalSeek GoOA Google Scholar Index Copernicus J-Gate Journal Citation Reports/Science Edition JournalGuide JournalTOCs KESLI-NDSL (Korean National Discovery for Science Leaders) Meta Microsoft Academic MyScienceWork Naver Academic Naviga (Softweco) Primo Central (ExLibris) ProQuest (relevant databases) Publons QOAM (Quality Open Access Market) ReadCube Reaxys SCImago (SJR) SCOPUS Semantic Scholar Sherpa/RoMEO Summon (ProQuest) TDNet Text Mining Ulrich's Periodicals Directory/ulrichsweb WanFang Data Web of Science - Science Citation Index Expanded WorldCat (OCLC) Yewno Discover Supplementary Materials Author''s Ethical Statements Editorial Policy Data Sharing Policy Article Processing Charges Instruction for Authors Privacy Statement Guidelines for Reviewers Open Access License Publication Ethics Statement Topics Biochemistry Human Biology Life Sciences Molecular Biology External Links Journal Archive Open Access Statement Crosscheck Plagiarism Screening Online Submission of Manuscripts Open Access Statement Crosscheck Plagiarism Screening Privacy Statement Volume 32 Issue 1 January 2021 Unable to retrieve citations for this document × Retrieving citations for document... Laboratory diagnostic value of neopterin measurements in patients with COVID-19 infection Dietmar Fuchs, Magnus Gisslen January 29, 2021 Page range: 1-4 More Cite Open Access PDF PDF Abstract The new coronavirus SARS-CoV-2 was identified to be responsible for the COVID-19 pandemic. There are striking differences in the response to infection, some people develop no or mild symptoms, while other outcomes are severe of even fatal. For those COVID-19 patients who require hospitalization, prognostic markers could help clinicians to identify patients with a poor outcome early. The serum levels of the immune activation marker neopterin have already been shown to be of prognostic value in patients with SARS-CoV-1 and a similar pattern can be observed for SARS-CoV-2. This comment discusses the biochemical circuits that support the clinical value of neopterin measurements in COVID-19 patients. Unable to retrieve citations for this document × Retrieving citations for document... Norepinephrine was superior in death risk reducing and hemodynamics compared to dopamine in treatment of patients with septic shock Xudong Lu, Xianghua Xu, Yueying Wu February 21, 2021 Page range: 5-10 More Cite Open Access PDF PDF Abstract Background To investigate the clinical effects of norepinephrine versus dopamine in treatment of septic shock by pooling the data form open published clinical trials. Material and Methods The clinical trials relevant to norepinephrine versus dopamine in treatment of septic shock were electronically searched in the databases of Pubmed, Embase, the Cochrane Library, Web of Science, Google scholar and CNKI. The original data related to the treatment effects such as death risk, oxygen metabolism and hemodynamics index were extracted from the included original studies. The death risk was pooled by the effect size of relative risk (RR), the oxygen metabolism and hemodynamics index were pooled by standard mean difference (SMD) and the corresponding 95% confidence interval (95%CI). The publication bias was evaluated by Begg's funnel plot and Egger's line regression test. Results Thirteen clinical trials were included in the meta-analysis. The pooled results demonstrated the death risk was significantly decreased (RR=0.89, 95%CI:0.81 to 0.98, p=0.024) in septic shock patients who received norepinephrine compared to those receiving dopamine. The HR (SMD=−1.84, 95%CI: −2.86 to −0.81, p<0.01) and cardiac index (SMD=−0.74, 95%CI: −1.01 to −0.48, p<0.01) were lower in norepinephrine group compared to dopamine group. The systemic vascular resistance index (SMD=1.33, 95%CI:0.62 to 2.04, p<0.01) in norepinephrine group was higher than those of dopamine group with statistical difference. The Begg's funnel plot and Egger's line regression test (t=−0.84, p=0.425) showed no publication bias. Conclusions Based on the present evidence, norepinephrine was superior to dopamine in the aspects of death risk reducing and hemodynamics. Unable to retrieve citations for this document × Retrieving citations for document... Clinical significance of serum homocysteine as a biomarker for early diagnosis of diabetic nephropathy in type 2 diabetes mellitus patients Bin Ye, Xiangying Zhu, Zhifu Zeng, Xiaozhen Ji, Meixia Ji March 25, 2021 Page range: 11-16 More Cite Open Access PDF PDF Abstract Objective The aim of this study was to investigate the clinical significance of serum homocysteine (Hcy) as a biomarker for early diagnosis of diabetic nephropathy (DN) in type 2 diabetes mellitus (T2DM) patients. Methods Fifty-five T2DM patients with DN and 51 T2DM patients without DN were prospectively recruited from January 2016 to May 2020 in our hospital. The serum Hcy was tested by electrochemiluminescence assay in DN and T2DM groups and compared. The diagnostic efficacy of serum Hcy as a biomarker for early diagnosis of DN was evaluated by calculating the diagnostic sensitivity, specificity and area under the ROC curve (AUC). Results The serum levels of Hcy were 15.49 ± 5.40 and 9.23 ± 3.15 μmol/L for DN and T2DM patients, respectively, with statistical difference ( t = 7.21, P < 0.001). In the DN group, the serum Hcy levels for patients with hyperfiltration, intermittent proteinuria, microalbuminuria, macroalbuminuria and uremic were 10.99 ± 2.57, 13.90 ± 2.86, 15.38 ± 4.77, 18.98 ± 4.36 and 23.31 ± 5.22 μmol/L, respectively, which indicated that serum Hcy levels in DN were higher than those of T2DM patients and correlated with patient’s renal damage. Using the serum Hcy level as the reference, the diagnostic sensitivity, specificity and AUC were 84.31 (71.41–92.98)%, 74.55 (61.00–85.33)% and 0.85 (0.78–0.92)%, respectively, with the cutoff value of 12.08 between DN and T2DM. The serum Hcy also had relatively good differential diagnostic efficacy between different DN stages with high sensitivity, specificity and AUC. Conclusion Serum Hcy was obviously elevated in DN compared to T2MD and correlated with the renal damage severity, which can be applied as a potential serological marker for early diagnosis of DN. Unable to retrieve citations for this document × Retrieving citations for document... The urinary biopterin in autism spectrum disorder Aleksandra Waligóra, Aleksandra Damasiewicz-Bodzek, Piotr Gorczyca, Sławomir Waligóra, Krystyna Tyrpień-Golder March 29, 2021 Page range: 17-22 More Cite Open Access PDF PDF Abstract Objective The aim of the study was to determine whether biopterin is present in significantly lower quantities in urine samples of patients with autism spectrum disorder (ASD) compared to healthy individuals. Methods The concentration of biopterin in urine samples was measured by ELISA using commercially available kit. The study involved 53 children aged 3–16 years with ASD and 60 healthy children aged 2–14 years. Results Significantly lower biopterin concentration was observed in autistic patients compared to the control group. However, no significant difference was observed between mild, moderate, and severe ASD. Conclusion One of the potential causes of decrease in urinary biopterin levels may be tetrahydrobiopterin (BH 4 ) deficiency, which has extensive and serious health consequences for the nervous system. The results of measuring biopterin as a fully oxidized form of BH 4 may suggest that biosynthesis or regeneration of BH 4 may be decreased in children with ASD. On the other hand, decreased urinary biopterin levels in children with ASD may be due to BH 4 overuse, a good regeneration process, and decreased urinary excretion; and abnormalities in BH 4 metabolism appear to be related to the aetiology of ASD or may be due to ASD. Volume 32 (2021) Issue 1 Volume 31 (2020) Issue 1 Volume 30 (2019) Issue 1 Volume 29 (2018) Issue 1 Volume 28 (2017) Issue 3-4 Issue 2 Issue 1 Volume 27 (2016) Issue 3-4 Issue 1-2 Volume 26 (2015) Issue 4 Issue 3 Issue 2 Issue 1 Volume 25 (2014) Issue 3-4 Issue 2 Issue 1 Volume 24 (2013) Issue 3-4 Issue 2 Issue 1 Special issue: 15th International Symposium on Pteridines and Folates, Antalya, Turkey, May 6–13, 2012 Volume 3 (2013) Issue 1-2 Issue 3 Volume 23 (2013) Issue 1 Volume 19 (2013) Issue 1 Volume 15 (2013) Issue 2 Issue 3 Issue 1 Issue 4 Volume 11 (2013) Issue 2 Issue 4 Issue 3 Issue 1 Volume 22 (2013) Issue 1 Volume 13 (2013) Issue 2 Issue 4 Issue 1 Issue 3 Volume 16 (2013) Issue 4 Issue 3 Issue 1 Issue 2 Volume 21 (2013) Issue 1 Volume 17 (2013) Issue 2 Issue 1 Issue 3 Issue 4 Volume 14 (2013) Issue 2 Issue 3 Issue 1 Volume 20 (2013) Issue 1 Volume 18 (2013) Issue 1 Volume 12 (2001) Issue 4 Issue 3 Issue 2 Issue 1 Volume 10 (1999) Issue 4 Issue 3 Issue 2 Issue 1 Volume 9 (1998) Issue 4 Issue 3 Issue 2 Issue 1 Volume 8 (1997) Issue 3 Issue 2 Issue 1 Volume 7 (1996) Issue 4 Issue 3 Issue 1-2 Volume 6 (1995) Issue 4 Issue 3 Issue 2 Issue 1 Volume 5 (1994) Issue 4 Issue 3 Issue 2 Issue 1 Volume 4 (1993) Issue 4 Issue 3 Issue 2 Issue 1 Volume 2 (1990) Issue 3 Issue 2 Issue 1 Volume 1 (1989) Issue 4 Issue 3 Issue 2 Issue 1 5-year Impact Factor 0.550 Cite Score 0.6 Index Copernicus Value 145.31 Impact Factor 0.366 SCImago Journal Rank 0.159 Source Normalized Impact per Paper 0.234 Submit MANUSCRIPTS Translational Neuroscience encourages the submission of both substantial full-length bodies of work and shorter manuscripts that report novel findings. There are no specific length restrictions for the overall manuscript or individual sections; however, we urge the authors to present and discuss their findings in a concise and accessible manner. All submissions must be made via online submission system Editorial Manager. In case of problems, please contact the Managing Editor of this journal (jedrzej.daszkiewicz@degruyter.com). For detailed information, please see Instruction for Authors. EDITORIAL POLICY Unpublished material: Submission of a manuscript implies that the work described is not copyrighted, published or submitted elsewhere, except in abstract form. The corresponding author should ensure that all authors approve the manuscript before its submission. Ethical conduct of research: The authors must describe and confirm safeguards to meet ethical standards when applicable. See Editorial Policy for details. Conflict of interest: When authors submit a manuscript, they are responsible for recognizing and disclosing financial and/or other conflicts of interest that might bias their work and/or could inappropriately influence his/her judgment. If no specified acknowledgement is given, the Editors assume that no conflict of interest exists. Authors are encouraged to fill in the ICMJE Conflicts of Interest Form (available here) and send it in the electronic format to the Managing Editor. Copyright: All authors retain copyright, unless – due to their local circumstances – their work is not copyrighted. The copyrights are governed by the Creative-Commons Attribution Only license (CC-BY) which is compliant with Plan-S. We may also publish a paper under CC-BY-NC-ND license on author's request. The corresponding author grants the journal the license to use of the article, by signing the License To Publish. Scanned copy of license should be sent to the journal, as soon as possible. Authorship: Authorship should be limited to those who have made a significant contribution to the conception, design, execution, or interpretation of the reported study. All those who have made significant contributions should be listed as co-authors. Where there are others who have participated in certain substantive aspects of the research project, they should be named in an Acknowledgement section. The corresponding author should ensure that all appropriate co-authors (according to the above definition) and no inappropriate co-authors are included in the author list of the manuscript, and that all co-authors have seen and approved the final version of the paper and have agreed to its submission for publication. Peer Review process: Our standard policy requires each paper to be reviewed by at least two Referees and the peer-review process is single-blind. The Editors reserve the right to decline the submitted manuscript without review, if the studies reported are not sufficiently novel or important to merit publication in the journal. Manuscripts deemed unsuitable (insufficient originality or of limited interest to the target audience) are returned to the author(s) without review. The Editor seeks advice from experts in the appropriate field. Research articles and communications are refereed by a minimum of two reviewers, review papers by at least three. Authors are requested to suggest persons competent to review their manuscript. However, please note that this will be treated only as a suggestion, and the final selection of reviewers is exclusively the Editor's decision. The final decision of acceptance in made by Managing Editor or, in case of conflict, by the Editor-in-Chief. Scientific Misconduct: This journal publishes only original manuscripts that are not also published or going to be published elsewhere. Multiple submissions/publications, or redundant publications (re-packaging in different words of data already published by the same authors) will be rejected. If they are detected only after publication, the journal reserves the right to publish a Retraction Note. In each particular case Editors will follow COPE’s Core Practices and implement the advices. Editorial Editor-in-Chief Prof. Dr. Dietmar Fuchs (Division of Biological Chemistry, Innsbruck Medical University, Innsbruck, Austria) Editorial Board Prof. Dr. Terken Baydar (Department of Toxicology, Hacettepe University, Ankara, Turkey) Prof. Dr. Nenad Blau (Department of General Pediatrics, University Children's Hospital, Heidelberg, Germany) Prof. Dr. Keith Channon (John Radcliffe Hospital, University of Oxford, Oxford, UK) Prof. Dr. Basak Engin (Department of Toxicology, Gazi University, Ankara, Turkey) Prof. Dr. Steven P. Gieseg (Free Radical Biochemistry Laboratory, University of Canterbury, Christchurch, New Zealand) Dr. Viola Groehn (API Synthesis & Development, Schaffhausen, Switzerland) Prof. Dr. Steven S. Gross (Joan and Sanford I. Weill Medical School, Cornell University, New York, USA) Prof. Dr. Hiroshi Ichinose (Tokyo Institute of Technology, Fujita Health University School of Medicine, Yokohama, Japan) Prof. Dr. Greg Kapatos (Wayne State University School of Medicine, Detroit, USA) Dr. Piotr Koslinski (Department of Toxicology, Nicolaus Copernicus University, Torun, Poland) Dr. Katharina Kurz (Department of Internal Medicine, Innsbruck Medical University, Innsbruck, Austria) Prof. Dr. Aurora Martinez (Department of Biomedicine, University of Bergen, Bergen, Norway) Prof. Dr. Bohuslav Melichar (Department of Oncology, Palacký University Medical School, Olomouc, Czech Republic) Dr. Vojtech Parrak (NsP sv Cyrila a Metoda, Petrzalka, Bratislava, Slovakia) Prof. Dr. Godefridus Peters (VU University Hospital, Amsterdam, The Netherlands) Prof. Dr. Gilbert Reibnegger (Institute of Physiological Chemistry, Graz Medical University, Graz, Austria) Prof. Dr. Haruro Shintaku (Department of Pediatrics, Osaka City Medical School, Osaka, Japan) Prof. Dr. Knut Teigen (Department of Biochemistry and Molecular Biology, University of Bergen, Bergen, Norway) Prof. Dr. Anders H. Thomas (Department of Chemistry, Universidad Nacional de La Plata, La Plata, Argentina) Prof. Dr. Aristidis Michael Tsatsakis (Department of Forensic Sciences and Toxicology, University of Crete Medical School, Heraklion, Greece) Prof. Dr. Guenter Weiss (Department of Internal Medicine, Innsbruck Medical University, Innsbruck, Austria) Prof. Dr. Ernst R. Werner (Division of Biological Chemistry, Innsbruck Medical University, Innsbruck, Austria) Prof. Dr. Jeongbin Yim (Department of Microbiology, Seoul National University, Seoul, South Korea) Language Editors Eileen ABLONDI, Harvard Medical School, USA Dr Kate Grayson (University of Bristol, UK) Dr Laura McVeigh (University of New South Wales, Australia) Dr Morgan Milton (RTI International, USA) Zandile Nare (University of Edinburgh, UK) Associate Editor Qian (Kevin) Liu M.D. (Tianjin Lung Cancer Institute, Tianjin Medical University General Hospital, Tianjin, China) Editorial Office Publisher DE GRUYTER Poland Bogumiła Zuga 32A Str. 01-811 Warsaw, Poland T: +48 22 701 50 15 Editorial Contact Jędrzej Daszkiewicz, Managing Editor Jedrzej.Daszkiewicz@degruyter.com​ Open Access Details Online ISSN: 2195-4720 Type: Journal Language: English Publisher: De Gruyter First published: April 20, 1989 Publication Frequency: 1 Issue per Year Audience: Researchers in the fields of chemistry, biochemistry, clinical biochemistry, metabolic disorders, clinical chemistry, clinical immunology, immunology, laboratory medicine, biology, molecular biology, molecular medicine, nutrition, phytomedicine Contact us Customer Service Human Resources Press Contacts for authors Career How to join us Current Vacancies Working at De Gruyter Open Access Articles Books Funding & Support For Authors Publish your book Publish your journal article Abstracting & Indexing For Libraries & Trade Partners Electronic Journals Ebooks Databases & Online Reference Metadata Our Partner Publishers Rights & Permissons Repository Policy Free Access Policy About De Gruyter De Gruyter Foundation Our locations Help/FAQ Privacy Policy Terms & Conditions Legal Notice © Walter de Gruyter GmbH 2021